Compare HIT & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIT | LONA |
|---|---|---|
| Founded | 1964 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 81.5M |
| IPO Year | 2024 | 2020 |
| Metric | HIT | LONA |
|---|---|---|
| Price | $1.00 | $7.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.25 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 67.6K | 46.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,327,511.00 | N/A |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $69.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 70.99 | N/A |
| 52 Week Low | $0.85 | $4.21 |
| 52 Week High | $4.01 | $14.21 |
| Indicator | HIT | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 50.92 |
| Support Level | $0.99 | $6.86 |
| Resistance Level | $1.16 | $9.78 |
| Average True Range (ATR) | 0.06 | 0.58 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 10.10 | 47.06 |
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.